Fasting levels of growth hormone as a predictive marker of cardiovascular risk

A sample comprising:

• a complex of at least one binder, and
• bodily fluid obtained from said subject at fasting level
• wherein said binder is at least one monospecific binder, having a binding affinity of 10−8M or less to hGH and its isoforms and wherein said binder(s) is either specific for one of the secreted hGH isomers, or for more than one or is specific for and binds to all secreted isomers of hGH selected from the group comprising isomer 1, isomer 2, isomer 3 and isomer 4 (SEQ ID. NO:
• 1 to 4)
• wherein said sample was prepared by binding the fasting level of human growth hormone (hGH), and/or its isoforms in said bodily fluid to said binder using an ultrasensitive hGH assay, wherein the ultrasensitive hGH assay has an analytical assay sensitivity of less than 100 pg/ml;
• and
• wherein the fasting level of hGH and/or its isoforms in said bodily fluid is above 340 pg/ml or below 60 pg/ml, and
• wherein said subject is male.

A sample comprising:

• a complex of at least one binder, and
• bodily fluid obtained from said subject at fasting level;
• wherein said binder is a monospecific binder having a binding affinity of 10−8M or less to hGH and its isoforms and wherein said at least one monospecific binder is specific for one of the secreted hGH isomers, for more than one of the secreted hGH isomers, or is specific for and binds to all secreted isomers of hGH selected from the group consisting of isomer 1, isomer 2, isomer 3 and isomer 4 (SEQ ID NO:
• 1 to 4),
• wherein said sample was prepared by binding the fasting level of human growth hormone (hGH), and/or its isoforms in said bodily fluid to said binder using an ultrasensitive hGH assay, wherein the ultrasensitive hGH assay has an analytical assay sensitivity of less than 100 pg/ml;
• and
• wherein the fasting level of hGH and/or its isoforms is from 340 pg/ml to 60 pg/ml, and
• wherein said subject is male.

A sample comprising:

• a complex of at least one binder, and
• bodily fluid obtained from said subject at fasting level;
• wherein said binder is a monospecific binder having a binding affinity of 10−8M or less to hGH and its isoforms and wherein said at least one monospecific binder is specific for one of the secreted hGH isomers, for more than one of the secreted hGH isomers, or is specific for and binds to all secreted isomers of hGH selected from the group consisting of isomer 1, isomer 2, isomer 3 and isomer 4 (SEQ ID NO:
• 1 to 4), and
• wherein the fasting level of hGH and/or its isoforms is above 340 pg/ml or below 60 pg/ml, and
• wherein said subject is male.